During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Perrigo Company PLC (NYSE:PRGO)

  • Dividend Yield: 8.13%
  • Canaccord Genuity analyst Susan Anderson maintained a Buy rating and cut the price target from $20 to $17 on Feb. 27, 2026. This analyst has an accuracy rate of 56%.
  • JP Morgan analyst Chris Scott maintained a Neutral rating and slashed the price target from $20 to $18 on Dec. 15, 2025. This analyst has an accuracy rate of 65%.
  • Recent News: On Aug. 5, Perrigo reported better-than-expected second-quarter financial results and affirmed its FY26 adjusted EPS guidance above estimates.
  • Benzinga Pro’s real-time newsfeed alerted to latest PRGO news.

Pfizer Inc (NYSE:PFE)

  • Dividend Yield: 6.15%
  • Guggenheim analyst Vamil Divan maintained a Buy rating and cut the price target from $35 to $31 on Aug. 7, 2026. This analyst has an accuracy rate of 79%.
  • BMO Capital analyst Evan David Seigerman maintained an Outperform rating and slashed the price target from $34 to $30 on July 13, 2026. This analyst has an accuracy rate of 58%.
  • Recent News: On Aug. 14, Valneva SE (NASDAQ:VALN) and its partner Pfizer announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for PF-07307405, their Lyme disease vaccine candidate.
  • Benzinga Pro’s real-time newsfeed alerted to latest PFE news

Bristol-Myers Squibb Co (NYSE:BMY)

  • Dividend Yield: 3.75%
  • Argus Research analyst Jasper Hellweg upgraded the stock from Hold to Buy with a price target of $75 on Aug. 5, 2026. This analyst has an accuracy rate of 55%.
  • Citigroup analyst Geoff Meacham maintained a Neutral rating and increased the price target from $66 to $70 on Aug. 3, 2026. This analyst has an accuracy rate of 75%
  • Recent News: On Aug. 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to Bristol Myers Squibb’s Zenbexus (iberdomide) for adult patients with multiple myeloma.
  • Benzinga Pro’s real-time newsfeed alerted to latest BMY news

Photo via Shutterstock